Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $14.4252W HIGH $26.74
Volume
150.27 K
Value Traded
5.99 M
Short % Float
4.86%
-1.86%Week
-0.27%1 Month
+8.36%3 Month
+39.02%6 Month
-67.59%5 Year
+2.06%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
578.59 M
EPS (TTM)
-1.52
P/E Ratio
-
Ent. Value
689.80 M
Total Shares
26.11 M
Float Shares
18.06 M
Insiders
30.81%
Institutions
64.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
KIDS Catalyst Timeline
Dated clinical, regulatory and corporate events for OrthoPediatrics Corp.
Past FDA Catalysts and PDUFA Decisions
How KIDS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
OrthoPediatrics Corp. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every KIDS program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pelizzon David RDirector, 10% Owner | Sell | -302,369 6,201,764 held | $21.01 | 09/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KIDS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.5 % (66.7 %) | 14.01 M | 732.14 K | 39.34% ( 206.70 K) |
KIDS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KIDS ranks across every disease it competes in
Competitive Position is a premium feature
See how KIDS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKIDS News
KIDS▲ +2.2%today
OrthoPediatrics Sponsors the 10th Pediatric Orthopedic Surgical Techniques Course
OrthoPediatrics Corp. sponsored the 10th Pediatric Orthopedic Surgical Techniques Course, which attracted 39 participants from 23 institutions across three countries. The course, aimed at senior residents and early-career surgeons, featured expert-led instruction and hands-on learning. A new companion manual was also introduced to enhance the educational experience.
Read more →KIDSOrthoPediatrics Surpasses 1,000 PNP Tibia Nail Implantations
OrthoPediatrics Corp. has announced the successful implantation of its 1,000th PNP Tibia Nail, a specialized device designed for pediatric patients. The PNP Tibia System allows for the treatment of tibia fractures in children, utilizing a unique 7mm cannulated nail. This innovative product addresses a significant gap in pediatric orthopedic care and is set to expand into European markets in 2027.
Read more →KIDSOrthoPediatrics Announces Full Commercial Launch of 3P™ Pediatric Plating Platform® Hip System Following More Than 350 Successful Implantations
OrthoPediatrics has announced the full commercial launch of its 3P Pediatric Plating Platform Hip System after a successful limited launch period with over 350 surgical implantations. The system is now available to pediatric orthopedic surgeons across the United States and represents a significant advancement in trauma and deformity correction. This launch is expected to enhance treatment options for pediatric patients.
Read more →KIDS▲ +6.8%on this news
OrthoPediatrics Corp. Reports Second Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics Corp. reported strong financial results for Q2 2026, achieving record revenues and adjusted EBITDA. The company helped nearly 46,000 children and saw significant growth in its Trauma & Deformity segment. However, it also faced challenges with a slight increase in net loss and a decline in scoliosis revenue. The company has raised its full-year revenue guidance, reflecting confidence in its growth trajectory.
Read more →KIDSOrthoPediatrics to Participate in the Canaccord Genuity 46th Annual Growth Conference
OrthoPediatrics Corp. has announced its participation in the Canaccord Genuity 46th Annual Growth Conference. CEO Dave Bailey and CFO Fred Hite will engage in a fireside chat on August 12, 2026, at 9:00 am ET. An audio webcast will be available on the company's investor relations website, along with a replay post-event.
Read more →KIDSOrthoPediatrics Corp. to Report Second Quarter Financial Results on August 4, 2026
OrthoPediatrics Corp. will announce its second quarter 2026 financial results on August 4, 2026, after market close. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss the results. Investors can access the call via a live and archived webcast on the company's website.
Read more →KIDSOSSIO Inc.’s Distribution Deal With OrthoPediatrics Corp. Brings Bio-Integrative, Metal-Free OSSIOfiber® Implants to U.S. Children’s Hospitals Nationwide
OSSIO Inc. has entered a distribution agreement with OrthoPediatrics Corp. to provide OSSIOfiber® implants to children's hospitals across the U.S. This partnership aims to improve pediatric orthopedic care with innovative, metal-free solutions. The bio-integrative nature of OSSIOfiber® is expected to enhance patient outcomes.
Read more →KIDSOrthoPediatrics Announces Distribution Agreement with OSSIO, Inc. to Provide Revolutionary Orthopedic Fixation Technology to U.S. Children’s Hospitals Nationwide
OrthoPediatrics Corp. has entered an exclusive distribution agreement with OSSIO, Inc. to provide a bio-integrative, metal-free fixation technology for pediatric patients. This innovative technology aims to reduce the need for secondary surgeries associated with metal implants. OSSIOfiber implants integrate with the patient's bone, enhancing healing and minimizing complications. The partnership is expected to strengthen OrthoPediatrics' market position and address more pediatric orthopedic needs.
Read more →KIDSUNFO and OrthoPediatrics Partner to Bring Non-Invasive Foot Brace for Newborns to U.S. Market
UNFOMed Ltd. has partnered with OrthoPediatrics to introduce the UNFO foot brace for Metatarsus Adductus in the U.S. This FDA-approved device offers a non-invasive alternative to painful casting and surgery, significantly improving the treatment experience for newborns. Developed by Dr. Izak Daizade, the brace has shown a 95% success rate in clinical use.
Read more →KIDSOrthoPediatrics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
OrthoPediatrics Corp. announced its participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Fred Hite, the COO and CFO, will engage in a fireside chat on June 8, 2026. The event will be accessible via an audio webcast on the company's investor relations website, with a replay available post-event.
Read more →KIDSOrthoPediatrics Corp. Reports First Quarter 2026 Financial Results and Increases 2026 Financial Guidance
OrthoPediatrics Corp. reported a strong first quarter for 2026, with total revenue reaching $59.4 million, marking a 13% increase from the previous year. The company recorded improvements in adjusted EBITDA and free cash flow, alongside increases in both domestic and international revenue. Despite the growth, OrthoPediatrics still faced a net loss of $10.7 million, the same as the prior year. The company has raised its full year revenue guidance, reflecting confidence in continued business expansion.
Read more →KIDSOrthoPediatrics Expands Specialty Bracing Portfolio with TRAXIO Halo Gravity Traction System
OrthoPediatrics Corp. has launched the TRAXIO Halo Gravity Traction System, expanding its Specialty Bracing portfolio. This product is designed for controlled spinal realignment in pediatric patients, utilizing a weight-and-pulley mechanism within hospital settings. The system aims to enhance safety and provide a continuum of care for scoliosis treatment. The collaboration with Synetik Group strengthens OrthoPediatrics' commitment to advancing pediatric orthopedic solutions.
Read more →KIDSOrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
OrthoPediatrics Corp. has announced the release date for its first quarter 2026 financial results, set for April 30, 2026, after market close. The company will hold a conference call at 4:30 p.m. ET on the same day to discuss these results. Investors can access the call via a live and archived webcast on the company's website.
Read more →KIDSOrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
OrthoPediatrics Corp. will participate in the 25th Annual Needham Virtual Healthcare Conference. CEO Dave Bailey and CFO Fred Hite are scheduled for a fireside chat on April 14, 2026, at 9:30 am ET. An audio webcast will be available on the company's investor relations website, with a replay offered post-event.
Read more →KIDS▲ +7.8%on this news
OrthoPediatrics to Participate in Upcoming Conferences
OrthoPediatrics Corp. (KIDS) announced its participation in two upcoming investor conferences, including the TD Cowen 46th Annual Health Care Conference and The Citizens Life Sciences Conference. The events will feature fireside chats, with webcasts available for those unable to attend live. The company continues to focus on pediatric orthopedics, offering over 85 products.
Read more →KIDS▲ +6.4%on this newsshared move
OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2025 Financial Results
OrthoPediatrics Corp. reported strong financial results for the fourth quarter and full year 2025, achieving a record revenue of $236.3 million, a 15% increase compared to 2024. The company generated its first positive free cash flow in history during Q4, amounting to $10 million. Despite a net loss of $39.6 million, up slightly from 2024, management reiterated confidence in growth, projecting 2026 revenues to increase by 11% to 13%. The company also highlighted the support of over 37,500 children in the latest quarter, emphasizing its commitment to pediatric orthopedics.
Read more →KIDSOrthoPediatrics Corp. to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
OrthoPediatrics Corp. has announced that it will release its financial results for the fourth quarter and full year of 2025 on February 26, 2026, following the market close. A conference call to discuss these results is scheduled for the same day at 4:30 p.m. ET. The company, which focuses exclusively on pediatric orthopedics, offers a wide array of products aimed at improving the lives of children with orthopedic conditions.
Read more →KIDSOrthoPediatrics Announces Expanded Enabling Technology Market Opportunity
OrthoPediatrics Corp. announced that its partner iotaMotion received FDA 510(k) clearance for the iotaSOFT Insertion System, now approved for children aged four and older. This robotic-assisted technology aims to improve cochlear implant surgeries by reducing variability. Cincinnati Children's Hospital is the first pediatric center to adopt this system, enhancing care for young patients.
Read more →About OrthoPediatrics Corp.
Headquarters2850 FRONTIER DRIVE, WARSAW, IN, 46582
BIOPHARMAWATCH ELITE PLUS
Trade the next KIDS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime